AI drug development has become an investment checklist, but scientific questions cannot be ranked by stock prices

The most expensive part of drug development has never been merely finding a molecule that looks appealing, but proving that it can produce effects in complex human biology that are reproducible, explainable, and sufficiently safe. Insider Monkey recently used hedge fund holdings as a clue to compile a group of listed companies categorized under the AI drug discovery theme, showing that capital markets still believe algorithms can change the timeline and cost structure of new drug development.

The signal from this kind of list is fairly direct: investors are looking for companies that can turn machine learning, structural biology, genomic data, clinical databases, or automated experimental platforms into commercial value. They may be biotech companies that directly design drug candidates, or companies that provide data, analytics platforms, or R&D infrastructure; although they are all placed within the “AI drug development” framework, their actual businesses may differ greatly.

For biomedicine, the core use cases of AI drug discovery broadly include target identification, molecular generation, prediction of protein structures and interactions, candidate screening, patient stratification in clinical trials, and the search for disease subtypes from real-world data. These tasks can indeed improve search efficiency in the early stages of R&D, but they are not clinical efficacy itself. Hypotheses proposed by models still have to pass through cell, animal, and human trials, as well as regulatory review, before they can become drugs that patients can use.

This is also where market rankings can easily blur the picture. Increased hedge fund holdings can reflect professional capital’s preference for an industry narrative, but they cannot show that a target has been validated, that a candidate molecule has demonstrated efficacy, or that a platform can reliably improve clinical success rates. In particular, the available source summary this time is quite limited and does not provide details on each company’s model performance, dataset quality, clinical progress, or peer comparisons, so it is even less appropriate to interpret an investment list as a scientific ranking.

**Background Context**

Recently, AI drug development has often been discussed as if it belonged in a single basket, but it includes at least two different businesses: one consists of drug development companies that advance their own pipelines and bear the risk of clinical failure; the other consists of data platform companies that turn genomic, medical record, imaging, or experimental data into R&D tools. The former must speak through drug candidates, while the latter must prove that data coverage, analytical quality, and medical workflows can genuinely support R&D or clinical decision-making.

The questions that truly need to be validated do not disappear because of the term AI. Are the training data biased toward specific populations or cancer types? Can the model reproduce its results in external datasets? Can predicted results lead to testable biological mechanisms? If a platform is used for clinical trial design or patient stratification, how should boundaries of responsibility and regulatory requirements be defined? These questions move more slowly than stock market enthusiasm, but they are closer to the underlying conditions that determine whether a drug can succeed.

Therefore, this list is more like a temperature map of the capital market than a biological answer. It reminds people that the imagination around AI drug development has not yet receded; at the same time, it also reminds researchers, physicians, and investors that what can truly put the industry on solid ground remains publicly verifiable data, clear experimental design, and results that can be proven useful in clinical settings.